Acute Myeloid Leukemia (AML) Clinical Trials

36 recruiting

Acute Myeloid Leukemia (AML) Trials at a Glance

51 actively recruiting trials for acute myeloid leukemia (aml) are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Phase 2 with 20 trials, with the heaviest enrollment activity in Suzhou, Houston, and New York. Lead sponsors running acute myeloid leukemia (aml) studies include The First Affiliated Hospital of Soochow University, Peking University People's Hospital, and Institute of Hematology & Blood Diseases Hospital, China.

Browse acute myeloid leukemia (aml) trials by phase

Treatments under study

About Acute Myeloid Leukemia (AML) Clinical Trials

Looking for clinical trials for Acute Myeloid Leukemia (AML)? There are currently 36 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Acute Myeloid Leukemia (AML) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Acute Myeloid Leukemia (AML) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 51 trials

Recruiting
Phase 2

Ivosidenib as Post-HSCT Maintenance for AML

Acute Myeloid Leukemia (AML)IDH1 MutationHematopoietic Stem Cell Transplant (HSCT)
Massachusetts General Hospital75 enrolled4 locationsNCT06707493
Recruiting
Phase 2

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center140 enrolled1 locationNCT06811233
Recruiting

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Acute Myeloid Leukemia (AML)
Technische Universität Dresden15,000 enrolled60 locationsNCT03188874
Recruiting

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)MLL Rearrangement
Peking University People's Hospital210 enrolled1 locationNCT07537738
Recruiting
Not Applicable

A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients

Relapsed or Refractory Acute Myeloid Leukemia (AML)MDS (Myelodysplastic Syndrome)
The First Affiliated Hospital of Soochow University30 enrolled1 locationNCT07500753
Recruiting
Phase 1Phase 2

Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS

Proton TherapyAcute Myeloid Leukemia (AML)Myelodysplastic Neoplasm+2 more
Institute of Hematology and Blood Transfusion, Czech Republic16 enrolled2 locationsNCT07532824
Recruiting
Phase 3

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.1,300 enrolled39 locationsNCT07007312
Recruiting
Phase 2

Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

Elderly PatientsNewly Diagnosed Acute Myeloid Leukemia (AML)
Chinese PLA General Hospital120 enrolled1 locationNCT07514936
Recruiting
Phase 2

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute52 enrolled2 locationsNCT06660368
Recruiting
Phase 1

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center18 enrolled7 locationsNCT05756777
Recruiting

Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML

Acute Myeloid Leukemia (AML)
Peking University People's Hospital100 enrolled1 locationNCT07500441
Recruiting
Phase 1

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Gastric CancerAdvanced Solid TumorTNBC - Triple-Negative Breast Cancer+1 more
SillaJen, Inc.260 enrolled15 locationsNCT05768932
Recruiting
Phase 1Phase 2

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission
Georgetown University24 enrolled3 locationsNCT04990102
Recruiting
Phase 3

MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Not Applicable

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Chronic Lymphocytic LeukemiaFollicular LymphomaSmall Lymphocytic Lymphoma+8 more
Masonic Cancer Center, University of Minnesota200 enrolled1 locationNCT01962636
Recruiting
Phase 1Phase 2

Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

Acute Myeloid Leukemia (AML)CEBPA MutationUnfit, New-diagnosis AML
The First Affiliated Hospital of Soochow University29 enrolled1 locationNCT07451912
Recruiting
Phase 2

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT06773208
Recruiting
Phase 1

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Acute Myeloid LeukemiaRefractory Chronic Myelomonocytic LeukemiaChronic Myelomonocytic Leukemia+9 more
Solu Therapeutics, Inc105 enrolled7 locationsNCT06950034
Recruiting
Phase 2

Alternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML

Newly Diagnosed Acute Myeloid Leukemia (AML)Intensive Chemotherapy UnfitAge ≥60
First Affiliated Hospital of Zhejiang University25 enrolled5 locationsNCT07172204
Recruiting
Phase 1

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996